ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Esophageal neuroendocrine carcinoma: molecular insights, diagnostic advances, and emerging treatment strategies.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal neuroendocrine carcinoma (ENEC) is a rare and aggressive malignancy, characterized by its high-grade, poorly differentiated nature. Despite advancements in understanding neuroendocrine tumors (NETs), ENEC remains an under-researched and poorly understood entity, presenting significant challenges in both diagnosis and treatment. Molecular studies have revealed frequent mutations in TP53 and RB1, along with genetic profiles paralleling small cell lung cancer (SCLC), suggesting shared oncogenic pathways that may guide targeted therapeutic approaches. However, the rarity of ENEC has limited the development of standardized treatment regimens, with most strategies borrowed from other malignancies such as SCLC. Current treatments, including platinum-based chemotherapy, show moderate success, yet response rates remain variable, particularly in advanced stages. The role of immunotherapy and targeted therapies is under investigation, with promising case reports but limited clinical evidence. Emerging diagnostic technologies, such as molecular profiling and liquid biopsy, offer enhanced precision in early detection and personalized treatment plans. Prognostic factors, such as Ki-67 proliferation index, serum biomarkers, and tumor stage, have shown significant associations with survival outcomes, though they remain under-explored in prospective clinical trials. Given the unique molecular features of ENEC, including high tumor mutational burden and distinct immune profiles, further research is essential to develop effective biomarkers, refine prognostic models, and create personalized, targeted therapies. This review aims to consolidate current knowledge on ENEC's molecular biology, diagnosis, and treatment, while identifying gaps in research and suggesting directions for future investigation to improve patient outcomes.
Indexed as
Identifiers
41507459What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.